Novavax (NVAX) Stock Overview
A biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NVAX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.89 |
| 52 Week High | US$9.20 |
| 52 Week Low | US$4.71 |
| Beta | 2.37 |
| 1 Month Change | 18.54% |
| 3 Month Change | -7.82% |
| 1 Year Change | -15.07% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -36.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVAX | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 9.3% | 1.8% | 0.3% |
| 1Y | -15.1% | 18.3% | 35.6% |
Return vs Industry: NVAX underperformed the Austrian Biotechs industry which returned 18.3% over the past year.
Return vs Market: NVAX underperformed the Austrian Market which returned 35.6% over the past year.
Price Volatility
| NVAX volatility | |
|---|---|
| NVAX Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in AT Market | 4.9% |
| 10% least volatile stocks in AT Market | 2.2% |
Stable Share Price: NVAX's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: NVAX's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 952 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.
Novavax, Inc. Fundamentals Summary
| NVAX fundamental statistics | |
|---|---|
| Market cap | €1.12b |
| Earnings (TTM) | €294.55m |
| Revenue (TTM) | €917.62m |
Is NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVAX income statement (TTM) | |
|---|---|
| Revenue | US$1.06b |
| Cost of Revenue | US$432.03m |
| Gross Profit | US$632.62m |
| Other Expenses | US$290.87m |
| Earnings | US$341.75m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.10 |
| Gross Margin | 59.42% |
| Net Profit Margin | 32.10% |
| Debt/Equity Ratio | -155.6% |
How did NVAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/19 09:14 |
| End of Day Share Price | 2026/01/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novavax, Inc. is covered by 24 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| George Zavoico | B. Riley Securities, Inc. |